These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 15709200

  • 1. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
    Clin Cancer Res; 2005 Feb 01; 11(3):1287-93. PubMed ID: 15709200
    [Abstract] [Full Text] [Related]

  • 2. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
    Int J Oncol; 2006 Sep 01; 29(3):713-9. PubMed ID: 16865289
    [Abstract] [Full Text] [Related]

  • 3. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S.
    Clin Cancer Res; 2004 Oct 15; 10(20):6821-9. PubMed ID: 15501958
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello M, D'Alessandro N.
    Int J Oncol; 2006 Apr 15; 28(4):923-30. PubMed ID: 16525642
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M.
    Mol Pharmacol; 2009 Aug 15; 76(2):290-300. PubMed ID: 19461054
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K.
    Expert Rev Anticancer Ther; 2003 Dec 15; 3(6):793-8. PubMed ID: 14686701
    [Abstract] [Full Text] [Related]

  • 7. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M.
    Clin Cancer Res; 2005 Aug 01; 11(15):5590-4. PubMed ID: 16061877
    [Abstract] [Full Text] [Related]

  • 8. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
    Arthritis Res Ther; 2005 Aug 01; 7(6):R1348-59. PubMed ID: 16277688
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E, Umezawa K.
    Biomed Pharmacother; 2006 Nov 01; 60(9):578-86. PubMed ID: 16978829
    [Abstract] [Full Text] [Related]

  • 10. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, Kuratomi Y, Yamamoto T, Weinstein IB, Komune S.
    Head Neck; 2006 Feb 01; 28(2):158-65. PubMed ID: 16355386
    [Abstract] [Full Text] [Related]

  • 11. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
    Urology; 2010 Apr 01; 75(4):805-12. PubMed ID: 20156648
    [Abstract] [Full Text] [Related]

  • 12. Ganoderic acids suppress growth and angiogenesis by modulating the NF-κB signaling pathway in breast cancer cells.
    Li F, Wang Y, Wang X, Li J, Cui H, Niu M.
    Int J Clin Pharmacol Ther; 2012 Oct 01; 50(10):712-21. PubMed ID: 22762853
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
    Takatsuna H, Morita S, Nagatsu T, Sawada M, Umezawa K.
    Biomed Pharmacother; 2005 Jul 01; 59(6):318-22. PubMed ID: 15932789
    [Abstract] [Full Text] [Related]

  • 14. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 15. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
    Ohsugi T, Kumasaka T, Okada S, Ishida T, Yamaguchi K, Horie R, Watanabe T, Umezawa K.
    Cancer Lett; 2007 Nov 18; 257(2):206-15. PubMed ID: 17764832
    [Abstract] [Full Text] [Related]

  • 16. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K, Morioka H, Nishimoto K, Suzuki Y, Susa M, Nakayama R, Kawai A, Sonobe H, Takaishi H, Ozaki T, Yabe H, Umezawa K, Toyama Y.
    Cancer Lett; 2008 Dec 18; 272(2):336-44. PubMed ID: 18760530
    [Abstract] [Full Text] [Related]

  • 17. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N, Miyakawa Y, Kohmura K, Umezawa K, Ikeda Y, Kizaki M.
    Leuk Res; 2007 Nov 18; 31(11):1529-35. PubMed ID: 17466373
    [Abstract] [Full Text] [Related]

  • 18. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A, Umezawa K, Bonavida B.
    Drug Resist Updat; 2007 Nov 18; 10(1-2):1-12. PubMed ID: 17306602
    [Abstract] [Full Text] [Related]

  • 19. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Shinoda K, Nakagawa K, Kosaka T, Tanaka N, Maeda T, Kono H, Mizuno R, Kikuchi E, Miyajima A, Umezawa K, Oya M.
    Hum Immunol; 2010 Aug 18; 71(8):763-70. PubMed ID: 20573582
    [Abstract] [Full Text] [Related]

  • 20. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling.
    Jiang J, Slivova V, Sliva D.
    Int J Oncol; 2006 Sep 18; 29(3):695-703. PubMed ID: 16865287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.